Group B streptococcus and high level resistance to aminoglycosides: Therapeutic implications for neonates [5];Streptocoque du groupe B et résistance à haut niveau aux aminosides: Implications thérapeutiques pour le nouveau-né

Archives de Pediatrie

Volumn 10, Issue 8, 2003, Pages 736-737

  Mariani Kurkdjian, P ^a   Benayoun, E ^a   Bingen, E ^a   Aujard, Y ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Aminoglycosides; Communicable diseases; Infant, newborn I; R factors; Streptococcus

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; GENTAMICIN; KANAMYCIN; PENICILLIN G; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; ENZYME MODIFICATION; FEMALE; HUMAN; IN VIVO STUDY; LETTER; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; NEWBORN; NONHUMAN; PATHOGENESIS; PLACENTAL TRANSFER; RIBOSOME; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; VAGINA;

EID: 0042014518     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(03)00344-0     Document Type: Letter

References (9)

1. Schauf V, Deveikis A, Riff L, Serota A. Antibiotic-killing kinetics of group B streptococci. J Pediatr 1976;89:194-8.
2. Swingle HM, Bucciarelli RL, Ayoub EM. Synergy between penicillins and low concentrations of gentamicin in the killing of group B streptococci. J Infect Dis 1985; 152:515-20.
3. Ounissi H, Derlot E, Carlier C, Courvalin P. Gene homogeneity for aminoglycoside-modifying enzymes in Gram-positive cocci. Antimicrob Agents Chemother 1990;34:2164-8.
4. Murdoch DR, Reller LB. Antimicrobial susceptibilities of group B Streptococci isolated from patients with invasive disease: 10-years perspective. Antimicrob Agents Chemother 2001;45:3623-4.
5. Betriu C, Gomez M, Sanchez A, Cruceyra A, Romero J, Picazo JJ. Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci. Antimicrob Agents Chemother 1994;38:2183-6.
6. Kim DS, Anthony BF. Penicillin tolerance in group B streptococci isolated from infected neonates. J Infect Dis 1981;144:411-9.
7. Labaune JM, Bleyzac N, Maire P, Jelliffe RW, Boutroy MJ, Aulagner G, et al. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Biol Neonate 2001;80:142-7.
8. Langhendries JP, Darimont J, Wallemacq P, Scalais E. Amikacine en dose unitaire en néonatologie: rythme optimal d'administration en fonction de l'âge gestationnel et de la pathologie. Lettre de l'Infectiologue 1995;HS:34-8.
9. Poyart C, Jardy L, Quesne G, Berche P, Trieu-Cuot P. Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital. Antimicrob Agents Chemother 2003;47:794-7.